CliffBio
biologic

Epogen/Procrit

epoetin alfa

Loss of exclusivityJune 2001projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameEpogen/Procrit
Active ingredientepoetin alfa
Strength2,000UNITS/ML
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalJune 1989
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Epogen/Procrit patent cliff — loss of exclusivity June 2001 | CliffBio